Press release
Sophion Bioscience, Inc. hires Chris Mathes as VP, General Manager for its North American operations
After a successful launch of the QPatch 16 system for automated patch clamping, Sophion Bioscience is now establishing a sales and support center on the North American East Coast. Chris Mathes, Ph.D. has been hired to head the operations as Vice President, General Manager.
Dr. Mathes has a background as an electrophysiologist from UCLA with postdoctoral positions at Stanford University and the Max Planck Institute in Göttingen, Germany. Since 1997, Dr. Mathes has been employed at Axon Instruments and Molecular Devices, where he has been a driving force behind the development and commercialization of the company’s automated patch clamp technology.
“I am very excited about the opportunity to lead the commercialization of this second-generation automated patch clamp system in North America, and placing the sales and support center on the East Coast seems ideal for reaching many of the pharma and biotech customers in the US,” says Dr. Mathes.
President of Sophion Bioscience, Inc. Dr. Torsten Freltoft is very satisfied with the reception of QPatch 16 by customers and clients. “Since the introduction of QPatch 16 we have had an overwhelming interest in the system, and we felt it was time to establish service and support closer to our North American customers,” says Dr. Freltoft. “With his unsurpassed network and large insight into the patch clamp field, I am very proud to welcome Dr. Mathes as head of the Sophion team in the US”.
QPatch 16 is an automated patch clamp system that provides high-quality patch clamp data on a truly industrial basis. The QPatch 16 is the first system in its class with integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The unique flow channel system implemented in the consumable QPlates enables fast liquid exchange around the cell and provides the option to test multiple compounds or concentrations on the same cell.
Introducing automated patch clamping into ion channel drug discovery potentially increases throughput by more than a factor 100 compared to traditional manual methods. In this way the pre-clinical research and development process becomes much more effective, ultimately providing better quality drugs faster.
For more information, please contact: Torsten Freltoft, President, Sophion Bioscience Inc., e-mail: tof@sophion.dk or telephone +45 4460 8811, or VP, General Manager Chris Mathes, e-mail: cma@sophion.dk. See also www.sophion.com.
page top
Join our mailinglist